Related Experiment Video
Updated: Apr 27, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.8K
[Spironolactone not effective in diastolic heart failure]
1Universitair Medisch Centrum Groningen, afd. Cardiologie, Groningen.
Nederlands Tijdschrift Voor Geneeskunde
|July 10, 2014
Summary
Spironolactone did not benefit patients with heart failure with preserved ejection fraction (HFpEF). Further research into diastolic heart failure pathophysiology is crucial for effective treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic systolic heart failure treatments have advanced, yet diastolic heart failure lacks evidence-based medical options.
- Spironolactone, previously effective for reduced ejection fraction heart failure, showed no benefit in preserved ejection fraction heart failure (HFpEF) in the TOPCAT trial.
Purpose of the Study:
- To evaluate the efficacy of spironolactone in patients with heart failure and preserved ejection fraction (HFpEF).
- To address the lack of effective medical treatments for diastolic heart failure.
Main Methods:
- The study analyzed data from the TOPCAT trial, focusing on patients with HFpEF.
- Primary endpoint included cardiovascular death or hospital admission for heart failure.
Main Results:
- Spironolactone did not demonstrate a significant benefit on the primary composite endpoint in HFpEF patients.
- This finding contrasts with its known efficacy in heart failure with reduced ejection fraction (HFrEF).
Conclusions:
- Current evidence does not support spironolactone for treating HFpEF.
- Improved understanding of HFpEF pathophysiology is essential for developing future therapeutic strategies.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
1.4K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
01:30Heart Failure V: Medical Management
621
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
01:22Heart Failure Drugs: β-Blockers
2.5K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.5K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K